The first gene therapy to restore hearing: A historic FDA decision and a new challenge for healthcare systems
On April 23, 2026, the FDA approved Regeneron's Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy for the treatment of genetic hearing loss associated with mutations in the OTOF gene.
This is a historic event in medicine.
This is not about compensating for lost function, but about therapy aimed at restoring the impaired biological mechanism of hearing.
Until now, severe congenital hearing loss in OTOF-associated disease was considered an irreversible condition requiring primarily technical and rehabilitative correction - hearing aids and cochlear implantation.
What is OTOF-associated hearing loss?
This is a rare A genetic disorder in which the function of the protein otoferlin is impaired.
Otoferlin is necessary for the transmission of sound signals from the sensory cells of the inner ear to the auditory nerve.
With mutations in the OTOF gene, the structures of the inner ear may remain anatomically intact, but signal transmission to the central nervous system is disrupted.
As a result, the child develops severe to profound congenital sensorineural hearing loss.
How Otarmeni Works
Otarmeni is an in vivo gene therapy based on an adeno-associated viral (AAV) vector.
The drug delivers a functional copy of the OTOF gene to cells of the inner ear, which should restore otoferlin production and auditory signal transmission.
The therapy is administered once and is surgically injected directly into the cochlea of the inner ear.
What the study showed
Approval is based on the results of the CHORD study.
According to Regeneron:
Why this decision is especially important
This is the first approved drug that aims not to compensate for the consequences of hearing loss, but to eliminate the molecular cause of the disease.
This is the first time the FDA has approved a therapy that could potentially restore a function previously considered irreversibly lost.
This is an important precedent for orphan medicine:
Gene therapy is moving beyond replacing a deficient protein and is increasingly becoming a tool for functional restoration.
A New Challenge for Healthcare Systems
Regeneron's announcement that the drug will be provided to patients in the US free of charge has attracted particular attention.
However, it is important to interpret this decision correctly: we are talking about providing the drug itself, and not about eliminating the cost of treatment as a whole.
The use of such therapy requires:
Why this is important
This is an important precedent for the entire field of rare diseases, as the first approved gene therapy for genetic hearing loss aims to address the cause of the disease and potentially restore function previously thought irreversibly lost.
Source:
FDA Approves First-Ever Gene Therapy Treatment for Genetic Hearing Loss Under National Priority Voucher Program
Regeneron - Otarmeni™ approved by FDA as the first and only gene therapy for genetic hearing loss
This is a historic event in medicine.
This is not about compensating for lost function, but about therapy aimed at restoring the impaired biological mechanism of hearing.
Until now, severe congenital hearing loss in OTOF-associated disease was considered an irreversible condition requiring primarily technical and rehabilitative correction - hearing aids and cochlear implantation.
What is OTOF-associated hearing loss?
This is a rare A genetic disorder in which the function of the protein otoferlin is impaired.
Otoferlin is necessary for the transmission of sound signals from the sensory cells of the inner ear to the auditory nerve.
With mutations in the OTOF gene, the structures of the inner ear may remain anatomically intact, but signal transmission to the central nervous system is disrupted.
As a result, the child develops severe to profound congenital sensorineural hearing loss.
How Otarmeni Works
Otarmeni is an in vivo gene therapy based on an adeno-associated viral (AAV) vector.
The drug delivers a functional copy of the OTOF gene to cells of the inner ear, which should restore otoferlin production and auditory signal transmission.
The therapy is administered once and is surgically injected directly into the cochlea of the inner ear.
What the study showed
Approval is based on the results of the CHORD study.
According to Regeneron:
- 80% of participants achieved clinically significant hearing improvement
- 42% achieved normal hearing at longer follow-up
- Some patients regained the ability to perceive whispered speech
Why this decision is especially important
This is the first approved drug that aims not to compensate for the consequences of hearing loss, but to eliminate the molecular cause of the disease.
This is the first time the FDA has approved a therapy that could potentially restore a function previously considered irreversibly lost.
This is an important precedent for orphan medicine:
Gene therapy is moving beyond replacing a deficient protein and is increasingly becoming a tool for functional restoration.
A New Challenge for Healthcare Systems
Regeneron's announcement that the drug will be provided to patients in the US free of charge has attracted particular attention.
However, it is important to interpret this decision correctly: we are talking about providing the drug itself, and not about eliminating the cost of treatment as a whole.
The use of such therapy requires:
- specialized genetic diagnostics
- selection patients
- surgical administration
- specialized infrastructure
- postoperative follow-up
- audiological monitoring and long-term outcome assessment
Why this is important
This is an important precedent for the entire field of rare diseases, as the first approved gene therapy for genetic hearing loss aims to address the cause of the disease and potentially restore function previously thought irreversibly lost.
Source:
FDA Approves First-Ever Gene Therapy Treatment for Genetic Hearing Loss Under National Priority Voucher Program
Regeneron - Otarmeni™ approved by FDA as the first and only gene therapy for genetic hearing loss
News
🧬 IQVIA published a report on the sustainability of biosimilar markets in Europe.
In the UAE, for the first time outside the USA, an adult patient with SMA has been administered the gene therapy Itvisma
Chiesi acquires KalVista: the first oral drug for the treatment of attacks of hereditary angioedema